were not refrigerated but stored and transported at the ambient Ghanaian temperature.
An advantage of this method is that it alleviates the need to transport whole blood between laboratories. This method almost certainly renders the samples non-infective for lipid-enveloped viruses such as HIV and hepatitis B, because guanidinium thiocyanate is a powerful protein denaturant used for extracting RNA from tissues rich in ribonucleases.' Triton X-100 is also a potent nonionic surfactant which, in combination with a solvent, has been shown to produce more than 10"-fold reduction in HIV-1 infectivity. 4 These substances disrupt the viral membranes, essentially dissociating the viral genome from its receptor, making it incapable of infecting host cells. occasion (96, 54-138 and 92, 63-122). In neither group did the LAP score show any correlation with age, duration of illness, haemoglobin concentration, white cell count, neutrophil count, paraprotein concentration or bone marrow plasma cell count.
Discussion
The only previous report comparing LAP score in patients with multiple myeloma and MGUS showed a difference between the two groups similar to that of the present study. 5 In that study nearly half of the myeloma patients, including all treated patients, had a LAP score within the normal range. In our study we found that all but one patient with myeloma had a raised LAP score, irrespective of the disease course. None of the patients with multiple myeloma had any known cause for a raised LAP score. LAP scoring is a simple test routinely performed in most of the laboratories. One advantage of LAP scoring over some other tests is that it is performed on peripheral blood film, thus avoiding invasive procedures like bone marrow aspiration. Its value in differentiating malignant from benign paraproteinaemia, however, seems to be limited. A normal LAP score is suggestive of a benign condition but a high score does not have a clear diagnostic value. Whether the patients with MGUS with a high LAP score will eventually develop multiple myeloma can only be determined by long term follow up. 
